Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study-Reference-Cited by-同舟云学术

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

Published:2017-09-04 Issue:4 Volume:177 Page:1033-1042
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Bissonnette R.¹^ORCID,Luger T.²,Thaçi D.³,Toth D.⁴,Messina I.⁵,You R.⁶,Guana A.⁵,Fox T.⁷,Papavassilis C.⁷,Gilloteau I.⁷,Mrowietz U.⁸

Affiliation:

1. Innovaderm Research Inc; Montréal QC Canada

2. Department of Dermatology; University of Münster; Münster Germany

3. Comprehensive Center for Inflammation Medicine; University Hospital Schleswig-Holstein; Lübeck Germany

4. XLR8 Medical Research; Windsor ON Canada

5. Novartis Pharmaceuticals; East Hanover NJ U.S.A.

6. Novartis Beijing Novartis Pharma Co. Ltd; Shanghai China

7. Novartis Pharma AG; Basel Switzerland

8. Psoriasis-Center; Department of Dermatology; University Medical Center Schleswig-Holstein; Kiel Germany

Funder

Novartis Pharma

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.15706/fullpdf

Reference20 articles.

1. Secukinumab in plaque psoriasis: results of two phase 3 trials;Langley;N Engl J Med,2014

2. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE);Blauvelt;Br J Dermatol,2015

3. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE);Paul;J Eur Acad Dermatol Venereol,2015

4. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis;Mease;N Engl J Med,2015

5. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial;McInnes;Lancet,2015

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review of the Factors Affecting the Redefinition of Therapeutic Use in Metropolitan Cities during the Emerging and Re-emerging Pandemics;Romanian Journal of Military Medicine;2024-09-01

2. Investigating EGFR, BRAF, and RAS Mutations in Oral and Cutaneous Squamous Cell Neoplasms: A Preliminary Report on Romanian Patients;Romanian Journal of Military Medicine;2024-09-01

3. Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation;PLOS ONE;2024-08-09

4. Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis;Expert Review of Clinical Pharmacology;2024-07-12

5. Biologics for Psoriasis;Dermatologic Clinics;2024-07